Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins
Authors:
- Jeffrey P. ThompsonJTJeffrey P. Thompson
- Waldemar DebinskiWDWaldemar Debinski
- 1 August 2001
- journal article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 39 (1-2) , 87-98
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Novel anti–brain tumor cytotoxins specific for cancer cellsNature Biotechnology, 1998
- Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991Journal of Neurosurgery, 1998
- cDNA Cloning and Characterization of the Human Interleukin 13 Receptor α ChainJournal of Biological Chemistry, 1996
- Receptor for Interleukin (IL) 13 Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma CellsJournal of Biological Chemistry, 1996
- Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α ChainJournal of Biological Chemistry, 1996
- Histopathology, classification, and grading of gliomasGlia, 1995
- Structural comparisons among the short-chain helical cytokinesStructure, 1994
- An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxinBioconjugate Chemistry, 1994
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993
- Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily.Journal of Experimental Medicine, 1990